Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $181,089.79 in Stock

Posted by George Bondi on Jun 24th, 2026

Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson bought 8,183 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were acquired at an average cost of $22.13 per share, for a total transaction of $181,089.79. Following the completion of the transaction, the chief financial officer owned 8,183 shares of the company’s stock, valued at approximately $181,089.79. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sensei Biotherapeutics Price Performance

FTH traded up $0.54 on Wednesday, reaching $24.54. The company’s stock had a trading volume of 102,858 shares, compared to its average volume of 78,057. Sensei Biotherapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $36.76.

Sensei Biotherapeutics News Summary

Here are the key news stories impacting Sensei Biotherapeutics this week:

Positive Sentiment: CEO Anand Kiran Parikh bought 2,806 shares at $19.76 each, signaling confidence in Sensei Biotherapeutics’ outlook. CEO purchase SEC filing
Positive Sentiment: CFO Brian C. Stephenson bought 9,230 shares at $24.36 each, a larger insider purchase that can be viewed as a strong vote of confidence from management. CFO purchase SEC filing
Positive Sentiment: HC Wainwright reiterated a Buy rating and $60 price target, while lifting forecasts across multiple future periods, reinforcing a bullish long-term view of the stock. HC Wainwright research note
Neutral Sentiment: HC Wainwright’s estimates still call for losses over the next several quarters and years, so the outlook remains highly speculative and dependent on future clinical or operational progress.

Analysts Set New Price Targets

A number of research firms have recently weighed in on FTH. BTIG Research raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Finally, HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a report on Monday. They set a “buy” rating and a $60.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sensei Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $60.00.

Read Our Latest Research Report on Sensei Biotherapeutics

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.